KR20150132131A - 약물 전달 담체로서 생체분해가능하고 임상적으로 상용가능한 나노입자 - Google Patents

약물 전달 담체로서 생체분해가능하고 임상적으로 상용가능한 나노입자 Download PDF

Info

Publication number
KR20150132131A
KR20150132131A KR1020157024176A KR20157024176A KR20150132131A KR 20150132131 A KR20150132131 A KR 20150132131A KR 1020157024176 A KR1020157024176 A KR 1020157024176A KR 20157024176 A KR20157024176 A KR 20157024176A KR 20150132131 A KR20150132131 A KR 20150132131A
Authority
KR
South Korea
Prior art keywords
nanoparticle
nanoparticles
core
airna
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020157024176A
Other languages
English (en)
Korean (ko)
Inventor
치앙 제이. 리
요우즈이 리
케유르 가다
바이브하브 사제나
치아오슈 다이
조셉 프라타
나미타 도드와드카르
Original Assignee
1글로브 헬스 인스티튜트 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 1글로브 헬스 인스티튜트 엘엘씨 filed Critical 1글로브 헬스 인스티튜트 엘엘씨
Publication of KR20150132131A publication Critical patent/KR20150132131A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K47/48861—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ceramic Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020157024176A 2013-02-05 2014-02-05 약물 전달 담체로서 생체분해가능하고 임상적으로 상용가능한 나노입자 Withdrawn KR20150132131A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361761012P 2013-02-05 2013-02-05
US61/761,012 2013-02-05
PCT/US2014/014751 WO2014123935A1 (en) 2013-02-05 2014-02-05 Biodegradable and clinically-compatible nanop articles as drug delivery carriers

Publications (1)

Publication Number Publication Date
KR20150132131A true KR20150132131A (ko) 2015-11-25

Family

ID=51300093

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157024176A Withdrawn KR20150132131A (ko) 2013-02-05 2014-02-05 약물 전달 담체로서 생체분해가능하고 임상적으로 상용가능한 나노입자

Country Status (13)

Country Link
US (2) US11001840B2 (enExample)
EP (2) EP3845248A1 (enExample)
JP (1) JP6507102B2 (enExample)
KR (1) KR20150132131A (enExample)
AU (2) AU2014215421A1 (enExample)
CA (1) CA2899155A1 (enExample)
ES (1) ES2873600T3 (enExample)
IL (1) IL240148A0 (enExample)
MX (1) MX2015010083A (enExample)
RU (1) RU2015137815A (enExample)
SG (2) SG10201706968UA (enExample)
WO (1) WO2014123935A1 (enExample)
ZA (1) ZA201506530B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014123935A1 (en) 2013-02-05 2014-08-14 1Globe Health Institute Llc Biodegradable and clinically-compatible nanop articles as drug delivery carriers
WO2015013673A1 (en) 2013-07-25 2015-01-29 Aurasense Therapeutics, Llc Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
US10434064B2 (en) 2014-06-04 2019-10-08 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
EP3183007B1 (en) 2014-08-19 2020-06-17 Northwestern University Protein/oligonucleotide core-shell nanoparticle therapeutics
CA2968531A1 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
EP3247796A4 (en) * 2015-01-14 2018-07-11 Exicure, Inc. Nucleic acid nanostructures with core motifs
KR102617833B1 (ko) 2016-05-06 2023-12-27 엑시큐어 오퍼레이팅 컴퍼니 인터류킨 17 수용체 mRNA의 특이적 녹다운을 위한 안티센스 올리고뉴클레오티드 (ASO)를 제시하는 리포좀성 구형 핵산 (SNA) 구축물
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
US10800817B2 (en) 2016-12-19 2020-10-13 Morehouse School Of Medicine Compositions and methods for treating diseases by inhibiting exosome release
EP3568122B1 (en) * 2017-01-10 2023-10-04 Dukebox SP. Z O.O. A method of manufacturing a suspension of nanoparticles of potassium salt or magnesium salt
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
KR102120482B1 (ko) 2018-10-05 2020-06-08 씨제이제일제당 (주) 생분해성 고분자 나노입자를 포함하는 메모리 소자 및 이의 제조방법
JP2022540665A (ja) * 2019-07-12 2022-09-16 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 機能化されたナノ粒子および細菌感染症の治療におけるその使用
WO2021067952A1 (en) * 2019-10-04 2021-04-08 The University Of Chicago Targeted nanomedicine for treating vascular disorders
EP4100021A4 (en) * 2020-02-03 2023-11-15 Rutgers, the State University of New Jersey MICRORNA-7 COMPOSITIONS FOR PROMOTING FUNCTIONAL RECOVERY AFTER SPINAL CORD INJURY AND METHODS OF USE THEREOF
US11998615B2 (en) 2021-04-14 2024-06-04 The Board Of Trustees Of The Leland Stanford Junior University Functionalized nanoparticles and their use in treating bacterial infections

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219577A (en) 1990-06-22 1993-06-15 The Regents Of The University Of California Biologically active composition having a nanocrystalline core
TW406020B (en) * 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5879715A (en) * 1997-09-02 1999-03-09 Ceramem Corporation Process and system for production of inorganic nanoparticles
DE19856432A1 (de) * 1998-12-08 2000-06-15 Basf Ag Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen
DE19912502A1 (de) 1999-03-19 2000-09-21 Inst Neue Mat Gemein Gmbh Nanoskalige Teilchen, Komplexe mit Polynukleotiden und deren Verwendung
AU2002214854A1 (en) 2000-10-25 2002-05-06 Inex Pharmaceuticals Corporation Lipid formulations for target delivery
IN192520B (enExample) * 2001-08-01 2004-04-24 Univ Delhi
SG190613A1 (en) 2003-07-16 2013-06-28 Protiva Biotherapeutics Inc Lipid encapsulated interfering rna
ATE470433T1 (de) 2004-02-13 2010-06-15 Nod Pharmaceuticals Inc Partikel mit kern aus calciumphosphat- nanopartikeln, biomolekül und gallensäure, herstellungsverfahren und therapeutische verwendung
US7611690B2 (en) 2005-01-04 2009-11-03 Gp Medical, Inc. Nanoparticles for protein drug delivery
US20110081410A1 (en) 2005-06-28 2011-04-07 St. Marianna University, School Ofmedicine Therapeutic agent for local inflammation
CN100435784C (zh) 2005-07-25 2008-11-26 管晓虹 含有和包封中药成分的无机盐纳米粒子的制备方法
WO2008045806A2 (en) * 2006-10-06 2008-04-17 Microislet, Inc. Multilayered polyelectrolyte-based capsules for cell encapsulation and delivery of therapeutic compositions
MX2009011218A (es) 2007-04-17 2010-02-11 Baxter Int Microparticulas de acido nucleico para administracion pulmonar.
US20110038939A1 (en) * 2007-07-16 2011-02-17 Northeastern University Therapeutic stable nanoparticles
ES2873350T3 (es) * 2007-08-27 2021-11-03 1Globe Health Inst Llc Composiciones de ARN interferente asimétrico y usos de las mismas
EP2197454A4 (en) 2007-09-25 2012-07-04 Idexx Lab Inc PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF OLIGONUCLEOTIDES
JP4647706B2 (ja) 2007-12-14 2011-03-09 江崎グリコ株式会社 α−リポ酸ナノ粒子およびその調製方法
US20110038941A1 (en) 2007-12-27 2011-02-17 The Ohio State University Research Foundation Lipid Nanoparticle Compositions and Methods of Making and Using the Same
KR20110026424A (ko) 2008-05-13 2011-03-15 유니버시티 오브 워싱톤 중합체 캐리어
JP2012509904A (ja) 2008-11-26 2012-04-26 ユニバーシティ・オブ・カンザス 核酸送達組成物および核酸送達法
ES2381022T3 (es) 2008-12-19 2012-05-22 Biolitec Ag Nanopartículas de fosfato de calcio como vehículo de colorantes para la terapia fotodinámica
US9937128B2 (en) * 2009-08-03 2018-04-10 The University Of North Carolina At Chapel Hill Liposomes comprising a calcium phosphate-containing precipitate
JP2013504337A (ja) * 2009-09-14 2013-02-07 ナノハイブリッド カンパニー リミテッド 標的特異的ｓｉＲＮＡ−層状無機水酸化物ナノハイブリッド、その製造方法、及びナノハイブリッドを含有する腫瘍治療用の医薬組成物
JP5491119B2 (ja) * 2009-10-02 2014-05-14 日東電工株式会社 薬物含有微粒子を含む医薬組成物およびその製造方法
WO2011140024A2 (en) * 2010-05-03 2011-11-10 University Of Utah Research Foundation Nanoparticles produced from recombinant polymers and methods of making and using the same
WO2013040295A2 (en) * 2011-09-14 2013-03-21 University Of South Florida Divalent-metal coated nanoparticles for delivery of compositions into the central nervous system by nasal insufflation
CA2853689C (en) 2011-11-04 2020-06-30 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
US20130243699A1 (en) * 2011-12-07 2013-09-19 Regents Of The University Of Minnesota Biodegradable Magnetic Nanoparticles and Related Methods
ITRM20120480A1 (it) 2012-10-09 2014-04-10 Uni Degli Studi Camerino Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione.
WO2014123935A1 (en) 2013-02-05 2014-08-14 1Globe Health Institute Llc Biodegradable and clinically-compatible nanop articles as drug delivery carriers

Also Published As

Publication number Publication date
JP6507102B2 (ja) 2019-04-24
ES2873600T3 (es) 2021-11-03
IL240148A0 (en) 2015-09-24
ZA201506530B (en) 2018-11-28
US20160046936A1 (en) 2016-02-18
SG11201506116XA (en) 2015-09-29
CA2899155A1 (en) 2014-08-14
EP2953646A4 (en) 2017-02-15
WO2014123935A9 (en) 2014-10-23
EP2953646B1 (en) 2021-03-10
AU2018200903A1 (en) 2018-02-22
MX2015010083A (es) 2016-04-26
WO2014123935A1 (en) 2014-08-14
RU2015137815A (ru) 2017-03-13
HK1217906A1 (en) 2017-01-27
US20210230595A1 (en) 2021-07-29
AU2014215421A1 (en) 2015-08-13
SG10201706968UA (en) 2017-09-28
EP2953646A1 (en) 2015-12-16
JP2016513090A (ja) 2016-05-12
US11001840B2 (en) 2021-05-11
EP3845248A1 (en) 2021-07-07

Similar Documents

Publication Publication Date Title
US20210230595A1 (en) Biodegradable and clinically-compatible nanoparticles as drug delivery carriers
EP2549986B1 (en) Multi-compartmental macrophage delivery
Shahzad et al. Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles
Zhao et al. Dual-functional lipid polymeric hybrid pH-responsive nanoparticles decorated with cell penetrating peptide and folate for therapy against rheumatoid arthritis
JP2016513090A5 (enExample)
Hillman The use of plant-derived exosome-like nanoparticles as a delivery system of CRISPR/Cas9-based therapeutics for editing long non-coding RNAs in cancer colon cells
CN104983716A (zh) 肿瘤细胞膜/核膜双靶向肿瘤纳米药物缓释系统及其制备与应用
Warner et al. Liver-specific drug delivery platforms: applications for the treatment of alcohol-associated liver disease
Yan et al. Design of a novel nucleus-targeted NLS-KALA-SA nanocarrier to delivery poorly water-soluble anti-tumor drug for lung cancer treatment
CN102784398B (zh) 内皮抑素作为递送系统和化学合成的rna干扰分子组成的组合物及应用
Hou et al. Tumor targeted and GSH stimuli-response α‑lactalbumin nanotubes co-delivering doxorubicin and siRNA for cancer therapy
Hu et al. An engineered-exosome disguised multifunctional nanoplatform for enhanced chemo-photothermal therapy of triple-negative breast cancer
Zhao et al. Nanomaterials for acute myeloid leukemia therapy: Current progress and future perspectives
Liu et al. Enhanced glioblastoma selectivity of harmine via the albumin carrier
HK40047354A (en) Biodegradable and clinically-compatible nanoparticles as drug delivery carriers
CN113730580B (zh) Pd-l1抑制剂在制备药物或试剂盒中的用途
CN108904811A (zh) 一种基于适配体修饰的中空介孔二氧化硅共载质粒的多功能纳米药物的制备及其应用
Mandal DNA tetrahedron as nanoparticulated delivery system in combating diseases
Zhang et al. Formulating Spray-Dried Albumin-Modified Lipid Nanoparticles Encapsulating Acyclovir for Enhanced Pulmonary Drug Delivery
CN100553612C (zh) 一种c-FLIP反义寡核苷酸纳米粒的制备方法
HK1217906B (en) Biodegradable and clinically-compatible nanoparticles as drug delivery carriers
Kumar et al. Nanocarrier-mediated delivery targeting for pancreatic cancer
Liu et al. Aptamer-Based Drug Delivery Systems
Pan et al. Preparation of platelet membrane biomimetic nanocarriers and their interactions with transplacental barrier
CN118662443A (zh) 一种pH敏感脂质体、装载药物的脂质体、抑制药物促转移的共载脂质体及其制备方法和应用

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150904

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid